NovoCure (STU:038) NonCurrent Deferred Liabilities : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NovoCure NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NovoCure's non-current deferred liabilities for the quarter that ended in Mar. 2024 was €0.0 Mil.

NovoCure NonCurrent Deferred Liabilities Historical Data

The historical data trend for NovoCure's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure NonCurrent Deferred Liabilities Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

7.06

9.98

5.73

2.72

NovoCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															1.72	0.75	-	-	-

NovoCure NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of NovoCure's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (STU:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines